|
Patent landscape, scope, and claims: |
United States Drug Patent 6,287,599: Scope, Claims, and Landscape Analysis
US Patent 6,287,599, granted on September 11, 2001, to Bristol-Myers Squibb Company, covers methods of treating or preventing thrombotic disorders using apixaban. Apixaban, marketed as Eliquis, is a direct factor Xa inhibitor, a class of anticoagulants used to prevent blood clots. This analysis details the patent's claims, its territorial and temporal scope, and the surrounding patent landscape, offering insights for R&D and investment strategies.
What Does US Patent 6,287,599 Claim?
The core of US Patent 6,287,599 lies in its claims for a method of treatment.
Method of Treatment Claims
The patent primarily claims:
- Claim 1: A method for inhibiting thrombin generation in a subject, comprising administering to the subject an effective amount of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamide or a pharmaceutically acceptable salt thereof. This claim specifically identifies the chemical structure of apixaban.
- Claim 2: The method of claim 1, wherein the subject is a human.
- Claim 3: The method of claim 1, wherein the effective amount is from about 0.1 mg to about 500 mg of the compound per day.
- Claim 4: The method of claim 1, wherein the effective amount is from about 1 mg to about 200 mg of the compound per day.
- Claim 5: The method of claim 1, wherein the effective amount is from about 2.5 mg to about 20 mg of the compound per day.
- Claim 6: The method of claim 1, wherein the compound is administered orally.
- Claim 7: The method of claim 1, wherein the thrombotic disorder is deep vein thrombosis or pulmonary embolism.
- Claim 8: The method of claim 1, wherein the thrombotic disorder is a consequence of atrial fibrillation.
- Claim 9: The method of claim 1, wherein the thrombotic disorder is a consequence of myocardial infarction or stroke.
- Claim 10: The method of claim 1, wherein the compound is 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamide. This claim reiterates the compound by its chemical name.
Compound Claims
While the primary focus is on the method of use, the patent also implicitly covers the compound apixaban itself through its association with the claimed method. Earlier patents likely cover the composition of matter of apixaban.
What is the Temporal and Territorial Scope of US Patent 6,287,599?
The temporal and territorial scope of a patent is crucial for understanding market exclusivity.
Grant Date and Expiration
- Grant Date: September 11, 2001.
- Original Expiration Date: Twenty years from the filing date. The filing date for this patent application was March 23, 1999 (Application No. 09/276,072). Therefore, the original expiration date was March 23, 2019.
- Patent Term Extension (PTE): Due to the lengthy regulatory review process for pharmaceuticals, drug patents are often eligible for PTE. Information regarding a specific PTE for US Patent 6,287,599 would require examination of USPTO records and FDA Orange Book data. However, given the commercialization timeline of apixaban, any PTE would have extended the term beyond the original expiration. Eliquis received its first FDA approval in December 2012 [1]. The standard patent term for apixaban has since expired in many major markets.
Territorial Scope
- Jurisdiction: United States Patent and Trademark Office (USPTO).
- Protection: This patent provides exclusive rights within the United States of America. It does not grant rights in other countries. Separate patent applications and grants are required for international protection.
What is the Patent Landscape Surrounding US Patent 6,287,599?
The patent landscape for apixaban is extensive, involving multiple patents covering the compound, its synthesis, formulations, methods of use, and polymorphs. US Patent 6,287,599 is one piece of a larger intellectual property strategy.
Key Patents for Apixaban (Bristol-Myers Squibb/Pfizer)
Bristol-Myers Squibb and Pfizer, the developers of apixaban (Eliquis), have a robust patent portfolio. While US Patent 6,287,599 covers a specific method of treatment, other patents are foundational for apixaban's commercialization:
- Composition of Matter Patents: These are typically the most foundational patents, covering the molecule itself. Early patents on apixaban (e.g., EP 0564409B1, which matured into US patents) covered the chemical entity. These patents have largely expired, allowing for generic competition in many regions.
- Process Patents: These patents cover specific methods of synthesizing apixaban. These can provide an additional layer of protection, even after the composition of matter patent expires, by making it difficult or uneconomical for competitors to produce the drug.
- Formulation Patents: Patents covering specific drug formulations (e.g., tablet compositions, dissolution profiles, stability enhancers) can extend market exclusivity. Eliquis has various formulations, and patents covering these could be active.
- Polymorph Patents: Different crystalline forms of a drug molecule (polymorphs) can have different physical properties (e.g., solubility, stability) and may be separately patentable. Patents covering specific polymorphs of apixaban could have extended exclusivity.
- Method of Use Patents: US Patent 6,287,599 falls into this category, covering specific therapeutic applications. Other method of use patents might cover treatment of different conditions or specific patient populations.
Litigation and Exclusivity Challenges
The patent life of a blockbuster drug like apixaban is often marked by intense litigation. Generic manufacturers typically challenge existing patents, seeking to invalidate them or demonstrate non-infringement.
- Inter Partes Review (IPR): This USPTO proceeding allows third parties to challenge the validity of granted patents. Several IPRs have been filed challenging patents related to apixaban.
- District Court Litigation: Generic companies seeking to launch apixaban products initiate Paragraph IV certifications under the Hatch-Waxman Act, alleging that a listed patent is invalid or will not be infringed. This often leads to patent infringement lawsuits filed by the patent holder.
- Settlements and Licensing: Patent disputes can result in settlements, where generic companies agree to delay their market entry in exchange for a license or other considerations.
Generic Entry and Market Dynamics
With the expiration of key composition of matter patents, the market for apixaban is opening to generic competition. The timeline for generic entry varies by country due to differences in patent laws, regulatory pathways, and patent litigation outcomes.
- Key Markets: In the United States, generic versions of apixaban have begun to enter the market following patent expiries and litigation outcomes [2]. Similar trends are observed in Europe and other major pharmaceutical markets.
- Impact on Pricing: The introduction of generics significantly reduces drug prices, impacting revenue streams for the originator companies and creating cost-saving opportunities for healthcare systems and patients.
Competitive Landscape for Anticoagulants
Apixaban competes with other anticoagulants, including:
- Other Direct Oral Anticoagulants (DOACs): Rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). These drugs share similar therapeutic indications but differ in their mechanisms of action (factor Xa inhibitors vs. direct thrombin inhibitors) and pharmacokinetic profiles.
- Warfarin: A vitamin K antagonist, warfarin has been a standard anticoagulant for decades. While effective, it requires regular monitoring and has numerous drug and food interactions.
- Heparins: Injectable anticoagulants, primarily used in hospital settings or for specific acute conditions.
The patent landscape for these competing drugs also influences market dynamics. Innovations in drug delivery, formulation, and novel anticoagulant mechanisms continue to shape the therapeutic area.
Key Takeaways
US Patent 6,287,599 protects specific methods of treating thrombotic disorders using apixaban. While its original term has expired, its role in the apixaban patent strategy is significant, contributing to the drug's initial market exclusivity. The broader patent landscape for apixaban is complex, involving multiple patents on the compound, its synthesis, and various therapeutic applications, which has been a subject of extensive litigation. The entry of generic apixaban is now a dominant market force, driven by the expiration of core patents and ongoing legal challenges. Understanding this patent history is crucial for evaluating ongoing market exclusivity, potential litigation risks, and opportunities for generic manufacturers and investors.
Frequently Asked Questions
-
When did US Patent 6,287,599 originally expire?
US Patent 6,287,599, filed on March 23, 1999, had an original expiration date of March 23, 2019.
-
Does US Patent 6,287,599 cover apixaban itself (the molecule)?
No, this patent primarily covers methods of treating thrombotic disorders using apixaban. Composition of matter patents, typically granted earlier, cover the apixaban molecule.
-
What is the geographic reach of US Patent 6,287,599?
This patent provides exclusive rights only within the United States. Protection in other countries requires separate patent applications and grants in those respective jurisdictions.
-
Is apixaban currently protected by active patents?
While the original patent for the apixaban molecule has expired in many regions, Bristol-Myers Squibb and Pfizer hold numerous other patents covering formulations, polymorphs, and specific methods of use, some of which may still be active and contribute to market exclusivity.
-
What is the implication of generic apixaban entering the market for US Patent 6,287,599?
The entry of generic apixaban is a consequence of the expiration of core patents, including potentially the original composition of matter patents and, in some cases, the expiration or successful invalidation of method-of-use patents like US Patent 6,287,599. This allows for broader market access and price competition.
Citations
[1] U.S. Food and Drug Administration. (2012). FDA approves Eliquis (apixaban) to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Retrieved from FDA Press Announcements (Note: Specific press release URL may change; search for "Eliquis approval FDA 2012").
[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA Orange Book Database. (Note: This is a general reference for all FDA-approved drugs and their patent/exclusivity information).
More… ↓
⤷ Start Trial
|
